問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of Hematology & Oncology

Division of Radiation Therapy

Division of Thoracic Medicine

Division of General Internal Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-11-06

陳三奇Chen, San-Chi
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

109Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳三奇

List

136Cases

2023-07-28 - 2023-11-13

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting1Sites

Terminated4Sites

2019-01-24 - 2020-07-31

Phase II

Completed
Phase 1/2 Study of TAS-120 in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    TAS-120

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2021-10-13 - 2024-08-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2022-09-01 - 2024-07-15

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2019-04-01 - 2027-11-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2025-03-01 - 2030-02-01

Phase III

Active
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05)

  • Condition/Disease

    Gastric Cancer 、Gastroesophageal Junction Cancer

  • Test Drug

    Frozen Crystal Injection Frozen Crystal Injection Injection Injection Injection Film-Coated Tablets Injection

Participate Sites
5Sites

Recruiting5Sites

2024-04-10 - 2028-07-25

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-10-16 - 2024-04-30

Phase II

Completed
A Multi-indication, Single-treatment Arm, Open-label Phase 2 Study of Regorafenib and Nivolumab in Combination in Patients with Recurrent or Metastatic Solid Tumors

  • Condition/Disease

    Recurrent or metastatic solid tumor

  • Test Drug

    BAY 73-4506 (Regorafenib)Nivolumab

Participate Sites
3Sites

Recruiting3Sites

2025-05-31 - 2031-04-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-02-01 - 2027-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 6 7 8 9 10 14
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB